Table 3.
Procedural Details and Post-Procedure Outcomes
| Characteristics | Control Group (n = 39) | BBDC Group (n = 34) | P value |
|---|---|---|---|
| 125I Seed number, (mean ± SD) | 18.68±2.99 | 38.84±2.46 | 0.002‡ |
| Cumulative dose at reference point | 42.55±2.60 | 85.14±4.72 | 0.001‡ |
| Hospital stay, day (mean ± SD) | 11.45±5.29 | 12.53±4.67 | 0.596‡ |
| Stent size (diameter × length) | 0.463# | ||
| 10 × 60 mm | 27 | 20 | |
| 10 × 50 mm | 12 | 14 | |
| The reasons for death | |||
| Hepatic failure | 24 | 21 | 0.984# |
| Multiple organ metastasis | 8 | 9 | 0.589# |
| Gastrointestinal hemorrhage | 4 | 3 | 1.000* |
| Unknown cause | 3 | 1 | 0.618* |
| Follow-up anti-cancer treatments | |||
| Transarterial infusion chemotherapy | 17 | 16 | 0.450# |
| Intravenous chemical therapy | 14 | 12 | 1.000# |
| Immunotherapy | 8 | 6 | 0.776# |
Notes: *The Fisher’s exact test was used. #Pearson chi-square test was used. ‡Difference in the variance between the two groups (Mann–Whitney test).